Skip to Content

Notice

Pediatric Advisory Committee; Notice of Meeting; Correction

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice; correction.

SUMMARY:

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of August 12, 2015 (80 FR 48325). Phenylephrine Hydrochloride was incorrectly linked to DUREZOL (difluprednate ophthalmic emulsion) 0.05% because they were both listed as item number 1 in the numbered list of products to be discussed at the meeting. Phenylephrine Hydrochloride Ophthalmic Solution is a separate stand-alone drug that will be reviewed by the committee and should be listed as item number 2. The other drugs in the numbered list should be renumbered accordingly. This document corrects that error.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Lisa Granger, Office of Policy, Planning, Legislation, and Analysis, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In FR Doc. 2015-19729, appearing on page 48325, in the Federal Register of Wednesday, August 12, 2015, the following correction is made:Start Printed Page 50636

On page 48326, in the first column, the numbered list is corrected to read as follows:

1. DUREZOL (difluprednate ophthalmic emulsion) 0.05%,

2. Phenylephrine Hydrochloride Ophthalmic Solution,

3. ZYLET (loteprednol etabonate and tobramycin ophthalmic suspension),

4. BETHKIS (tobramycin Inhalation Solution),

5. INTELENCE (etravirine),

6. PREZISTA (darunavir),

7. VIRAMUNE XR (nevirapine),

8. EPIDUO (adapalene and benzoyl peroxide),

9. EXJADE (deferasirox),

10. DOTAREM (gadoterate meglumine),

11. FYCOMPA (perampanel),

12. RECOTHROM (thrombin, topical [recombinant]),

13. PREVNAR 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]),

14. PLEXIMMUNE,

15. ELANA SURGICAL KIT (HUD),

16. BERLIN HEART EXCOR PEDIATRIC VENTRICULAR ASSIST DEVICE (VAD),

17. ENTERRA THERAPY SYSTEM, and

18. CONTEGRA Pulmonary Valved Conduit.

Start Signature

Dated: August 14, 2015.

Jill Hartzler Warner,

Associate Commissioner for Special Medical Programs.

End Signature End Supplemental Information

[FR Doc. 2015-20541 Filed 8-19-15; 8:45 am]

BILLING CODE 4164-01-P